

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Description

CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.

Conference Call and Webcast Information:

Date:	Thursday, November 7, 2024 at 4:30 PM ET
Participant Dial-in (US):	1-800-717-1738
Participant Dial-in (International):	1-646-307-1865
Conference ID Code:	60579
Webcast Access:	Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at <https://www.relmada.com/investors/ir-calendar>.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’s lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

Investor Contact:

Tim McCarthy
LifeSci Advisors
Tim@lifesciadvisors.com



Source: Relmada Therapeutics

Released November 4, 2024

Date Created

2024/11/04